Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
Healthcare
$8.72 +1.13%
+$0.32 today
- Market cap
- $144.76M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
52W Low $6.70High $43.85
Volume 0.24M
Average 0.28M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$177.23M
FY 2025 · Annual
Investing Cash Flow
$45.01M
FY 2025 · Annual
-79.4% YoYFinancing Cash Flow
$44,000.00
FY 2025 · Annual
-100.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Depreciation & Amortization | 4.84M | 5.69M | 6.82M | 7.22M | 7.32M |
| Deferred Income Tax | 7.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.24M | 26.3M | 24.91M | 24.69M | 14.01M |
| Change in Working Capital | (17.62M) | 104.41M | (34.38M) | 8.9M | (50.4M) |
| Accounts Receivables | (6.9M) | 5.34M | (28.96M) | 27.46M | 4.64M |
| Inventory | (4.55M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 6.43M | (1.23M) | 4.81M | 706K | (2.47M) |
| Other Working Capital | (12.61M) | 100.29M | (10.23M) | (19.27M) | (52.57M) |
| Other Non-Cash Items | 6.16M | (13.65M) | (2.17M) | (4.88M) | 42.92M |
| Operating Cash Flow | (81.68M) | 3.55M | (111.62M) | (191.54M) | (177.23M) |
| Capital Expenditures | (15.32M) | (7.86M) | (4.32M) | (3.1M) | (1.7M) |
| Acquisitions (Net) | 0 | 28.74M | 0 | 0 | 0 |
| Purchases of Investments | (248.73M) | (216.67M) | (460.3M) | (461.52M) | (264.95M) |
| Sales of Investments | 166.73M | 189.5M | 460.69M | 683.13M | 311.66M |
| Other Investing Activities | 9K | (28.73M) | 0 | 0 | 0 |
| Investing Cash Flow | (97.32M) | (35.02M) | (3.92M) | 218.51M | 45.01M |
| Debt Repayment | 0 | (9.38M) | (12.5M) | (4.08M) | 0 |
| Common Stock Issued | 0 | 56.27M | 11.97M | 96.53M | 376K |
| Common Stock Repurchased | (7K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.25M | 1.42M | 138.08M | 1.61M | (332K) |
| Financing Cash Flow | 3.26M | 48.31M | 137.55M | 94.05M | 44K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (175.74M) | 16.84M | 22.01M | 121.02M | (132.17M) |
| Free Cash Flow | (97M) | (4.31M) | (115.93M) | (194.64M) | (178.93M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$191.1M
+ D&A$7.3M
+ Stock-Based Comp$14.0M
+ Deferred Tax$0
- Working Capital-$50.4M
+ Other Non-Cash$42.9M
= Operating Cash Flow-$177.2M
- Capex-$1.7M
= Free Cash Flow-$178.9M
Analysis
FY2025 free cash flow is -$178.9M. FCF conversion is 93.6% of net income. Operating cash flow was -$177.2M, with capex of -$1.7M. The largest bridge item is Working Capital at -$50.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 22, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
Does STRO generate free cash flow?
Sutro Biopharma, Inc. (STRO) generated -$178.93M of free cash flow in fiscal 2025.
How much operating cash flow does STRO produce?
Operating cash flow was -$177.23M, before capital expenditures of $1.70M.
Continue the stock analysis
Jump to another research area for this company.